Summary
GlobalData, the industry analysis specialist's new report, "Ulcerative Colitis-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global ulcerative colitis market. The report identifies the key trends shaping and driving the global ulcerative colitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ulcerative colitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global ulcerative colitis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global ulcerative colitis market.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ulcerative colitis.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global ulcerative colitis market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global ulcerative colitis market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global ulcerative colitis market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Ulcerative Colitis Market: Market Characterization 6
2.1 Overview 6
2.2 Ulcerative Colitis Market Size 6
2.3 Ulcerative Colitis Market Forecast and CAGR 6
2.4 Drivers and Barriers for Ulcerative Colitis Market 7
2.4.1 Drivers for Ulcerative Colitis Market 7
2.4.2 Barriers for Ulcerative Colitis Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Ulcerative Colitis Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Sales for Major Ulcerative Colitis Products 11
3.4 Product Profile for the Major Marketed Products in Ulcerative Colitis Market 11
3.4.1 Asacol 11
3.4.2 Lialda 12
3.4.3 Pentasa 13
3.4.4 Apriso 13
3.4.5 Colazal 14
3.4.6 Remicade 15
3.4.7 Azulfidine 15
3.5 Key Takeaway 18
4 Ulcerative Colitis Market: Pipeline Assessment 19
4.1 Overview 19
4.2 Strategic Pipeline Assessment 19
4.2.1 Technology Trends Analytic Framework 19 
4.3 Ulcerative Colitis Therapeutics-Promising Drugs under Clinical Development 20
4.4 Molecule Profile for Promising Drugs under Clinical Development 21
4.5 Prograf (Tacrolimus) 21
4.5.1 Overview 21
4.5.2 Efficacy 21
4.5.3 Safety 21
4.5.4 Clinical study Details 21
4.6 Vedolizumab 21
4.7 Abatacept 22
4.8 Adalimumab 22
4.9 Golimumab 23
4.10 Ulcerative Colitis Therapeutics Market-Clinical Pipeline by Mechanism of Action 23
4.11 Ulcerative Colitis Pipeline-Pipeline by Clinical Phases of Development 24
4.11.1 Ulcerative Colitis Therapeutics-Regulatory and Phase III Clinical Pipeline 25
4.11.2 Ulcerative Colitis Therapeutics-Phase II/III Clinical Pipeline 25
4.11.3 Ulcerative Colitis Therapeutics-Phase II Clinical Pipeline 26
4.11.4 Ulcerative Colitis Therapeutics-Phase I/II Clinical Pipeline 27
4.11.5 Ulcerative Colitis Therapeutics-Phase I Clinical Pipeline 27
4.11.6 Ulcerative Colitis Therapeutics-Preclinical Pipeline 27
4.12 Discontinued/Suspended Drugs for Ulcerative Colitis 28
4.13 Key Takeaway 28
5 Ulcerative Colitis Market: Implications for Future Market Competition 29
6 Ulcerative Colitis Market: Future Players in Ulcerative Colitis Market 30
6.1 Introduction 30
6.2 Bristol-Myers Squibb Company 30
6.2.1 Overview 30
6.2.2 Business Description 31
6.2.3 Autoimmune Diseases Portfolio 31
6.3 GlaxoSmithKline, Inc 32
6.3.1 Overview 32
6.3.2 Business Description 32
6.3.3 Autoimmune Diseases Portfolio 33
6.4 Pfizer Incorporated 33
6.4.1 Overview 33
6.4.2 Business Description 34
6.4.3 Autoimmune Diseases Portfolio 35
6.5 Salix Pharmaceuticals, Ltd 35
6.5.1 Overview 35
6.5.2 Business Description 35
6.5.3 Autoimmune Disease Portfolio 36
7 Ulcerative Colitis Market: Appendix 37
7.1 Definitions 37
7.2 Acronyms 37
7.3 Research Methodology 37
7.3.1 Coverage 38
7.3.2 Secondary Research 38
7.3.3 Forecasting 39
7.3.4 Primary Research 41
7.3.5 Expert Panel Validation 42
7.4 Contact Us 42
7.5 Disclaimer 42
7.6 Sources 43

List of Tables
1.1 List of Tables
Table 1: Global Ulcerative Colitis Therapeutics Market, Revenue Forecasts ($m), 2000-2008 7
Table 2: Global Ulcerative Colitis Therapeutics Market, Revenue Forecasts ($m), 2008-2015 7
Table 2: Major Marketed Products Comparison in Ulcerative Colitis Market , 2009 17
Table 3: Ulcerative Colitis Therapeutics-Most Promising Drugs Under Clinical Development, 2009 20
Table 4: Ulcerative Colitis Therapeutics-Phase III Clinical Pipeline, 2009 25
Table 5: Ulcerative Colitis Therapeutics-Phase II/III Clinical Pipeline, 2009 25
Table 5: Ulcerative Colitis Therapeutics-Phase II Clinical Pipeline, 2009 26
Table 6: Ulcerative Colitis  Therapeutics-Phase I/II Clinical Pipeline, 2009 27
Table 6: Ulcerative Colitis  Therapeutics-Phase I Clinical Pipeline, 2009 27
Table 9: Ulcerative Colitis  Therapeutics-Preclinical Pipeline, 2009 27
Table 7: List of Discontinued Drugs for Ulcerative Colitis, 2009 28
Table 12: Bristol-Myers Squibb-Autoimmune Diseases Pipeline, 2009 31
Table 13: Bristol-Myers Squibb-Ulcerative Colitis Pipeline, 2009 32
Table 14: GlaxoSmithKline-Autoimmune Diseases Pipeline, 2009 33
Table 15: GlaxoSmithKline-Ulcerative Colitis Pipeline, 2009 33
Table 16: Pfizer-Autoimmune Diseases Pipeline, 2009 35
Table 17: Pfizer-Ulcerative Colitis Pipeline, 2009 35
Table 18: Salix Pharmaceuticals-Autoimmune Diseases Pipeline, 2009 36
Table 19: Salix Pharamceuticals-Ulcerative Colitis Pipeline, 2009 36

List of Figures
1.2 List of Figures
Figure 1: Global Ulcerative Colitis Market Forecast 2000-2015, Revenue ($m) 6
Figure 2: Opportunity and Unmet Need in Ulcerative Colitis Market, 2009 9
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Ulcerative Colitis, 2009 10
Figure 4: Global Sales of Top Ulcerative Colitis Products, 2009 11
Figure 5: Technology Trends Analytic Framework of the Ulcerative Colitis Pipeline, 2009 19
Figure 6: Technology Trends Analytic Framework of the Ulcerative Colitis Pipeline-Description, 2009 20
Figure 7: Ulcerative Colitis Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009 24
Figure 8: Ulcerative Colitis Pipeline by Phase of Clinical Development, 2009 24
Figure 9: Implications for Future Market Competition in the Ulcerative Colitis Market, 2009 29
Figure 10: Ulcerative Colitis Therapeutics Market-Clinical Pipeline by Company, 2009 30
Figure 10: GlobalData Methodology 38
Figure 11: GlobalData  Market Forecasting Model 41